Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Hiroaki SoyamaMorikazu MiyamotoHiroko MatsuuraHideki IwahashiSoichiro KakimotoHiroki IshibashiTakahiro SakamotoTaira HadaJin SuminokuraMasashi TakanoPublished in: Cancer chemotherapy and pharmacology (2020)
The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome. Large-scale studies are needed to further examine these results.